New formoterol/ beclometasone inhaler strength

Prescribers have a new option for treating asthma, with the launch of both Fostair and Fostair NEXThaler (beclometasone/formoterol) in a 200 microgram/6 microgram strength.

Fostair (formoterol/beclometasone) delivers extrafine particles into the lungs, allowing a lower daily dose of corticosteroid to be given. | iStock
Fostair (formoterol/beclometasone) delivers extrafine particles into the lungs, allowing a lower daily dose of corticosteroid to be given. | iStock

Both Fostair 200/6 and Fostair NEXThaler 200/6 are licensed for the treatment of asthma where use of a combination product comprising a long-acting ß2-agonist and an inhaled corticosteroid is appropriate. Two inhalations are given twice daily.

Another recent change to the Fostair range was the addition of severe COPD to the licensed indications for Fostair NEXThaler 100/6. Both the Fostair 100/6 metered-dose inhaler and the Fostair NEXThaler 100/6 dry powder inhaler are now licensed for the symptomatic treatment of severe COPD and for the treatment of asthma.

Further information
View Fostair drug records 
Summaries of Product Characteristics
Manufacturer: Chiesi

Prescribers should note that the beclometasone doses in Fostair products are not equivalent to those delivered by non-extrafine formulations. Owing to the difference in particle sizes, 250 microgram beclometasone administered via a standard inhaler is therapeutically equivalent to 100 microgram beclometasone in a Fostair product when given via the NEXThaler device or the Fostair metered dose inhaler.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases